Daniel Vonderon

Daniel Vonderon inquired about the status of the casdatifan plus volrustomig frontline study, a collaboration with AstraZeneca, specifically asking for an update on its paused status and potential reopening.

Answer

CEO Terry Rosen clarified that the study was paused but patients continued dosing with a reduced volrustomig dose. He noted no additional immunities and no primary progression since the dose reduction, with ongoing discussions with AstraZeneca. He emphasized the focus on the CAS plus anti-PD-1/CTLA-4 arm in ARC-20.